Core Laboratories (CLB) Reports In-Line Q3 EPS, Q4 Guidance Misses

Core Laboratories (NYSE: CLB) reported Q3 EPS of $0.83, in-line with the analyst estimate of $0.83. Revenue for the quarter came in at $197.3 million versus the consensus estimate of $201.06 million.

Core Laboratories sees Q4 2015 EPS of $0.63-$0.67, versus the consensus of $0.75. Core Laboratories sees Q4 2015 revenue of $180 million, versus the consensus of $191.94 million.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• L3Harris CEO steps down amid conduct review, shares drop
• InspireMD (NSPR) Tops Q2 EPS by 1c